Clinical Trial Update: Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Revlimid (lenalidomide) at 25 mg with R-CHOP in follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• R-CHOP
• Revlimid (lenalidomide)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED